# clinical - LLM run 005

- Script: `llm-test/clinical-llm.py`
- Exit code: `0`

## Terminal Output

```text
No cooldown configured for this backend.

======================================================================
ANSWER
======================================================================
Backend: openai
Model:   qwen2.5:7b
```python
context = """
CLINICAL TRIAL DOCUMENT:

=== LONG-CONTEXT EVALUATION PROMPT — CLINICAL TRIAL RECORDS ===

[... full context provided above ...]

question = """
Q1 [Single-hop retrieval]:
What is the allergy flag currently recorded for subject PT-2247?
Answer with the exact flag value only. Do not explain.

Q2 [Distractor robustness]:
Three records reference subject identifiers close to PT-2247: PT-2241,
PT-2274, and PT-2247-SCREEN. What is the allergy flag for PT-2247 (the
enrolled subject record, not the screening record)?
Answer with the exact flag value only.

Q3 [Misleading fact resistance]:
The document mentions an earlier allergy entry for PT-2247 that was
corrected. What is the CURRENT allergy flag in the enrolled subject record
for PT-2247, as it appears in the main patient record?
Answer with the exact flag value only.

Q4 [Span extraction]:
Copy the exact sentence from the document that explains why PT-2247 is
flagged for enhanced renal monitoring.

Q5 [Multi-hop reasoning]:
Using only information present in this document:
- What drug and dose is PT-2247 receiving?
- What did the Phase I safety review committee recommend for subjects in
  that dose cohort?
Combine these two facts to explain what ongoing protocol action should
apply to PT-2247. Show your reasoning step by step.
"""

final_answer = """
Q1: PCN-HIGH
Q2: PCN-HIGH
Q3: PCN-HIGH
Q4: Treating physician: Dr. Anika Rao
Note: Subject PT-2247 is flagged for enhanced renal monitoring due to
creatinine trending above threshold at Week 12 visit (1.61 mg/dL).
Q5: The enrolled record shows that subject PT-2247 received Compound VX-7 with a high dose of 80mg. The Phase I safety review committee recommended continued monitoring of renal function markers for subjects in the high-dose arm. Therefore, ongoing protocol action for subject PT-2247 should involve heightened attention to their renal health as per the high-dose recommendation.
"""

print(final_answer)
```

======================================================================
LATENCY BREAKDOWN
======================================================================
  Total wall time:    57.730s

======================================================================
TOKEN USAGE
======================================================================
qwen2.5:7b: input=1,645, output=499, calls=1
======================================================================
```
